← The Wire
TBPHNasdaq
Theravance Biopharma, Inc.
Pharmaceutical Preparations · CA · CIK 1583107
Theravance Biopharma develops and commercializes medicines, earning revenue from collaborations and licensing
red 8-K · 90d⚡ Elevated coverage
$858M
Market cap
$17.06
Last close
-3.2%
1D
+3.0%
5D
3.1M
Volume
Price · last 39 sessions+0.9%
May 4L $15.58 · H $17.63Jun 29
261
Total filings
Jun 29, 2026
Last filing
12/31
Fiscal year end
DEF 14ADEF 14AApr 28, 2026DEF 14AFORM-DEF 14AApr 10, 2025DEF 14ADEF 14AApr 5, 2024DEF 14ADEF 14AMar 28, 2023DEF 14ADEF 14AMar 25, 2022DEF 14ADEF 14AMar 22, 2021DEF 14ADEF 14AMar 24, 2020DEF 14ADEF 14AMar 20, 2019DEF 14ADEF 14AMar 21, 2018DEF 14ADEF 14AApr 11, 2017DEF 14ADEF 14AMar 25, 2016
Insider Activity
In the 90 days to Mar 16, 2026: 1 sold $434K.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Mar 16, 2026 | Farnum RhondaSVP, COMM & MEDICAL AFFAIRS | Sell | 15,534 | $14.00 | $217K |
| Mar 16, 2026 | Farnum RhondaSVP, COMM & MEDICAL AFFAIRS | Sell | 7,767 | $13.92 | $108K |
| Mar 16, 2026 | Farnum RhondaSVP, COMM & MEDICAL AFFAIRS | Sell | 7,766 | $13.92 | $108K |
| Dec 3, 2025 | Farnum RhondaSVP, COMM & MEDICAL AFFAIRS | Sell | 15,534 | $18.75 | $291K |
| Dec 3, 2025 | Farnum RhondaSVP, COMM & MEDICAL AFFAIRS | Sell | 7,767 | $18.75 | $146K |
| Dec 3, 2025 | Farnum RhondaSVP, COMM & MEDICAL AFFAIRS | Sell | 7,766 | $18.75 | $146K |
| Nov 26, 2025 | Broshy EranDirector | Sell | 15,501 | $20.00 | $310K |
| Nov 26, 2025 | Broshy EranDirector | Sell | 14,000 | $20.00 | $280K |
| Nov 11, 2025 | Broshy EranDirector | Sell | 29,500 | $18.50 | $546K |
| Nov 11, 2025 | Broshy EranDirector | Sell | 15,500 | $18.50 | $287K |
| Nov 11, 2025 | Broshy EranDirector | Sell | 15,500 | $17.00 | $264K |
| Nov 11, 2025 | Broshy EranDirector | Sell | 15,500 | $17.00 | $264K |
| Nov 11, 2025 | Broshy EranDirector | Sell | 14,000 | $18.50 | $259K |
| Nov 11, 2025 | Broshy EranDirector | Sell | 14,000 | $18.50 | $259K |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.
In the News
⚡ Elevated coverageCoverage (30d): 2 reputable articles · skews ▲ positive.
ReutersZymeworks expands beyond cancer with $929 million Theravance acquisition22h agoBarron'sZymeworks to Buy Theravance for Lung Disease Drug. Both Stocks Are Sliding.23h ago
Reputable outlets only (Reuters, WSJ, CNBC, Barron's, and peers). More on Google News ↗
Similar companies
Comparable business profile · signals at a glance